Dapagliflozin+Sitaglipin from 45 companies, which can only be sold in September next year, has been approved. Analysts say that the number of licensed companies is increasing as Dongkoo and Daewon, which succeeded in developing products, start supplying generics. On the 28th, the MFDS approved 13 additional items of Dapagliflozin+Sitagliptin. As a result, the number of Dapagliflozin+Sitaglipin increased to 45. Forxiga is an SGLT-2 inhibitory diabetes treatment and has recently grown rapidly in the diabetes treatment market. Forxiga, the original drug, recorded 42.6 billion won in outpatient prescriptions (based on UBIST) last year. Januvia has long been leading the market with DPP-4 inhibitory drugs. MSD's Jan